Dova Pharmaceuticals (DOVA) Research Coverage Started at Wedbush
Investment analysts at Wedbush assumed coverage on shares of Dova Pharmaceuticals (NASDAQ:DOVA) in a research note issued to investors on Wednesday, Marketbeat reports. The brokerage set an “outperform” rating and a $19.00 price target on the stock. Wedbush’s target price indicates a potential upside of 90.19% from the company’s current price.
Several other research analysts have also recently weighed in on DOVA. BidaskClub upgraded shares of Dova Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Tuesday, May 14th. HC Wainwright set a $18.00 price objective on shares of Dova Pharmaceuticals and gave the stock a “buy” rating in a research report on Tuesday, March 5th. Finally, JPMorgan Chase & Co. cut shares of Dova Pharmaceuticals from an “overweight” rating to an “underweight” rating and decreased their price objective for the stock from $34.00 to $20.00 in a research report on Wednesday, January 23rd. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and six have given a buy rating to the stock. The stock presently has an average rating of “Buy” and an average price target of $28.25.
DOVA stock opened at $9.99 on Wednesday. The company has a current ratio of 4.46, a quick ratio of 4.27 and a debt-to-equity ratio of 0.20. The company has a market capitalization of $282.05 million, a P/E ratio of -3.84 and a beta of 2.06. Dova Pharmaceuticals has a 1-year low of $5.62 and a 1-year high of $35.33.
In related news, Director Paul B. Manning acquired 68,000 shares of the firm’s stock in a transaction that occurred on Thursday, March 7th. The shares were bought at an average cost of $7.48 per share, for a total transaction of $508,640.00. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 60.30% of the stock is currently owned by corporate insiders.
Institutional investors and hedge funds have recently modified their holdings of the business. Spark Investment Management LLC boosted its stake in Dova Pharmaceuticals by 31.8% in the first quarter. Spark Investment Management LLC now owns 80,500 shares of the company’s stock worth $715,000 after buying an additional 19,400 shares in the last quarter. Vanguard Group Inc. boosted its stake in Dova Pharmaceuticals by 2.5% in the third quarter. Vanguard Group Inc. now owns 619,604 shares of the company’s stock worth $12,993,000 after buying an additional 14,985 shares in the last quarter. Broadfin Capital LLC purchased a new stake in Dova Pharmaceuticals in the fourth quarter worth approximately $2,667,000. BlackRock Inc. boosted its stake in Dova Pharmaceuticals by 0.8% in the third quarter. BlackRock Inc. now owns 1,154,232 shares of the company’s stock worth $24,204,000 after buying an additional 9,312 shares in the last quarter. Finally, Sanders Morris Harris LLC purchased a new stake in Dova Pharmaceuticals in the first quarter worth approximately $2,507,000. 30.20% of the stock is owned by institutional investors and hedge funds.
About Dova Pharmaceuticals
Dova Pharmaceuticals, Inc, a pharmaceutical company, focuses on acquiring, developing, and commercializing drug candidates for thrombocytopenia disease. The company's lead product candidate is DOPTELET that is indicated for the treatment of thrombocytopenia in adult patients with chronic liver disease scheduled to undergo a procedure.
Read More: What is the float in trading stocks?
Receive News & Ratings for Dova Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dova Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.